Investing News NetworkYour trusted source for investing success

ovid therapeutics

Top NASDAQ Genetics Stocks

Ovid Provides 2020 Update for Rare Neurological Disease Platform

5 Top NASDAQ Biotech and Pharma Stocks: Sorrento Climbs

Ovid Therapeutics Reports Q3 Financial Results

Ovid Therapeutics’ First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial

5 Top Weekly NASDAQ Biotech & Pharma Stocks: Corvus Soars

Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101

Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock

Ovid Therapeutics Plans to Move into the Phase 3 Trial Based on End-of-Phase 2 Meeting for OV101

Ovid Presents Additional Data at AACAP

Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101

Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies

Blackstone Secures $22.6m for Mankayan Copper-Gold Drilling

C29 Metals shifts focus to Mayfield Copper Project

Equity Metals: Advancing High-grade, District-scale Silver and Gold Assets in British Columbia

South Harz Potash: A Globally Significant European Potash and Critical Minerals Opportunity

Ian Rodger Appointed Managing Director

South Harz Potash Limited

Equity Metals

Terra Clean Energy

BP

NevGold

FinEx Metals

MARKETS

COMMODITIES

CURRENCIES